2023 GPB Scientific Curate Biosciences launches its first product to transform cell therapy manufacturing costs and performance
2022 ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet
2022 ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine
2021 ILiAD Biotechnologies closes a $23.9 million Convertible Note Offering
June 2020 Seneca Therapeutics closed a $3 million Series A round.
2020 GPB Scientific Announces $25.5 Million Financing from Vensana Capital and Amgen Ventures
Read the full press release
2019-2020 ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center
Read the full press release
2019-2020 Seneca Therapeutics closed on a $780,000 KISS financing
June 2019 ILIAD Biotechnologies BPZE1 vaccine mentioned in CNN Report: Whooping cough vaccine becomes less effective over time, study says
2019 Seneca Therapeutics closed on a $500,000 KISS financing
2018 GPB Scientific closes $2.5 million convertible note round
Fall 2017 FORGE Life Sciences raises $500,000 from angel investors
Summer 2017 Illuminare Biotechnologies closed a $2.3M Series A round
July 2017 ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data
Read the full press release...
2017-2018 RenalSense raises $3.5 million from angel investors
2017 GPB Scientific raises $1.0 million from angel investors
2016-2017 ILiAD Biotechnologies raises $2.6 million from angel investors
Spring 2016 GPB Scientific raises $1.0 million from angel investors.
Spring 2016 ILiAD Biotechnologies raises $1.0 million from angel investors.
Fall 2015 GPB Scientific closes $1.6 million Series A round.
Fall 2015 RenalSense closes $3.6 million Series A round.
Fall 2015 ILiAD Biotechnologies closes $3.7 million financing round.
March 2014 CytoSorbents Corporation Announces $10.2 Million Registered Direct Offering.
Click here to read the full press release
March 2014 GPB Scientific raises $700,000 from angel investors.
November 2013 Callidus Biopharma acquired by Amicus Therapeutics (NASDAQ-FOLD) for $15 million upfront payment with potential milestone payments totaling $115 million. Click here to read the full press release
November 2013 Hygeia Therapeutics acquired by Stratus Media Group (OTCBB-SMDI).
Click here to read the full press release
October 2013 CytoSorbents raises $200,000 from angel investors.
May 2013 Callidus Biopharma announces $4.6 million Series A financing
Read the full press release
March 2013 Callidus Biopharma receives $3.0 million from strategic investors
December 2012 Callidus Biopharma successfully generates in vivo proof of concept data
January 2012 Callidus Biopharma receives $1.6 million from Angel and strategic investors
October 2011 Core Essence Orthopaedics launches PONTiS™, a novel endotendonous implant for minimally invasive repair of severed tendons
September 2011 Lerner Medical Devices closes on a $1M Angel financing
July 2011 Advanced BioHealing Acquired by Shire Pharmaceuticals for $750M
June 2011 WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise by China's Ministry of Commerce
March 2011 Core Essence Orthopaedics receives an $11.3M Series B round led by Baird Venture Partners
March 2011 WuXi PharmaTech announces collaboration with BMS for a new analytical and stability testing facility
October 2010 Core Essence Orthopaedics closes on a $2.9M Convertible Debt from Angel Investors
May 2011 QuantumBio and Chemical Computing Group announce release of DivCon Discovery Suite for MOE
March 2010 Hygeia Therapeutics closes on a $2.0M round from Angel Investors
November 2009 Lerner Medical Devices receives 510(k) clearance for Levia® Targeted Phototherapy for Self-Treatment at home
October 2009 WuXi PharmaTech receives 2009 Schering-Plough Excellence Award
December 2007 Lerner Medical Devices closes on a $3.3M Angel Round to develop Levia® device
2007 WuXi PharmaTech publicily listed in NYSE. Read More